A new report by DART Markets forecasts the overall world market for treating age-related macular degeneration (AMD or ARMD), diabetic retinopathy (DR) and other disorders of the retina will reach $17.38bn in 2020. That revenue forecast and others appear in Retinal Diseases: Wet and Dry AMD, Diabetic Retinopathy Market 2016-2026: Aflibercept, Ranibizumab, Bevacizumab, Verteporfin, Ocriplasmin, Anti-VEGF, Anti-PDGF, published in July 2016.
This 208-page report provides quantitative and qualitative information on 10-years revenue forecasts to 2026 at overall world market, disease submarkets, product (brand) and national market level presented in 121 charts and discussion. The study gives revenue predictions to 2026 for four therapeutic submarkets at world level:
- Wet age-related macular degeneration (wAMD)
- Dry AMD (dAMD)
- Diabetic retinopathy (DR)
- Other retinal diseases (grouped forecast).
The study also provides revenues and forecast of five prominent drugs to 2026:
This report discusses the competitive landscape in the retinal diseases drugs market, which includes discussion on SWOT, STEP, Leading Companies, and M&A activities in this market.
Research, data and analyses cover activities of leading companies in the retinal diseases drugs industry: - Roche
- Other manufacturers and marketers of ophthalmic pharmaceuticals
This new study also discusses leading pipeline candidates for Wet AMD, Dry AMD, and Diabetic Retinopathy, shows two interviews and predicts revenues to 2026 in 11 leading national markets.
The work analyses these national markets:
- EU5 (Italy, Spain, Germany, the UK and France)
- BRIC (Brazil, Russia, India and China)
- Rest of the World
This report also provides a separate chapter on Pricing, Reimbursement, Market Access and Regulations, providing insights on these national markets:
- Emerging Markets
Our reports have been used by over 10K customers, including:
Retinopathy Of Prematurity - Pipeline Review, H2 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Retinopathy Of Prematurity - Pipeline Review, H2 2018, provides an overview of the Retinopathy Of Prematurity (Ophthalmology) pipeline landscape. Retinopathy...
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Pipeline Review, H2 2018 Summary According to the recently published report ’Tumor Necrosis Factor Receptor Superfamily Member 6 - Pipeline...
Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 126.96.36.199) - Pipeline Review, H2 2018 Summary Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or...
The Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market size is expected to reach $1,180.7 million by 2024, rising at a market growth of 30.4% CAGR during the forecast period. Glaucoma is a progressive disease and is the major cause of irreversible blindness with an estimated burden to rise 111.8 million by 2040. This has increased...
Executive Summary A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Glaucoma Treatment Market. The report analyzes the global glaucoma treatment market By Indication...
Allergies Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Allergies Global Clinical Trials Review, H2, 2018" provides an overview of Allergies clinical trials scenario.This report provides top line data relating to the clinical trials on Allergies. Report...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.